Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Kansas City Chiefs and the Atlanta Braves don't have depictions of Native Americans. They have a tomahawk and the tip of a spear depicted in their logos respectively.
The Milwaukee Braves did have what looks like a war whooping Native American. I'm looking at those refrigerator magnet depictions now, but will probably settle on the present Atlanta Braves tomahawk and Chiefs Speer depictions for my historical collection.
The Milwaukee Braves moved to Atlanta in 1966 I think and lost the Native American depiction at that time, so the current fridge magnet depicting the Native American would not be historically accurate.
Update, I'm still waiting for delivery of my historical Mississippi flag.
Opened CARR at $23.80
Bought a slew of Indians and Redskins paraphernalia from Ebay. Cost much less than Amazon for the same items. Thanks for the heads up on these other teams. I don't follow organized sports, never did. Personally I don't care what they name themselves or who may object. Just happy to have a piece of antiquity. Still waiting to receive my Mississippi flag. It's in transit.
Me too, but they loose their luster when they go down and are unworkable. Then the only rationale I have for holding them is the dividend Not much value there to me. My preference is trading solid companies stock, and momentum stories.
The thread in all of the stocks I buy are that I would hold them for their intrinsic value. But value over time changes. What's valuable today isn't tomorrow. Conversely what wasn't valuable today is valuable tomorrow. In other words... well you know about the Spanish Inquisition.
From my perspective adding for the most part is mitigating a loss under certain circumstances. Though I am guilty of doing just that quite recently with EPD, I believe that was for good reason. If I can I'll get out of a position if it goes down then comes back up to my cost. Unless there is a clear reason to continue holding. Now this doesn't work many times in this market. Take NEE for example and WMT for another, but over all I've kept red down in my accounts and That's necessary.
Nick,
Reopened PFE with a .15 "dividend" after selling on a stop at 33.40, reopened at 33.25. Wanted 33.15, but didn't hit.
I've had a buy order in for TD for like forever at 42.80. Well, damn, I was finally able to chase it at 43.25
Opened TD at 43.25
Closed DOCU at 212.20 form 209.90 for today's round trip.
Not averse to making money Nick, dividends are fine and dandy. Since the March debacle I'm focused on rebuilding my dividend paying portfolios and taking capital gains whenever and wherever I can. That said. I'll be buying back a few stopped out of today.
Earlier on I had stated that we would see a "W" not a "V" "L" or "U" recovery.
Well, guess what, we're seeing a "W".
Closed DNB on another stop.
Top Stock Reports for Walmart, BHP & IBM
12:36 pm ET July 8, 2020 (Zacks) Print
Wednesday, July 08, 2020
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), BHP Group (BHP) and International Business Machines (IBM). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Walmart shares have only modestly lagged the Zacks Supermarkets industry over the past year (+12.5% vs. +13.8%), with the group benefiting from increased demand for essential items amid coronavirus.
Such trends drove the company in first-quarter fiscal 2021, wherein top and bottom lines rose year over year and beat the consensus mark, and U.S. comps grew for the 23rd straight time. Further, higher stay-at-home trends boosted e-commerce sales. Walmart has long been witnessing solid e-commerce sales, largely backed by grocery delivery.
Notably, it recently unveiled Express Delivery service to expedite deliveries amid coronavirus. The company is also undertaking other measures to support operations amid the pandemic, which however entail high costs and pose threats to the operating income. Also, the gross margin has been strained due to unfavorable mix and pricing.
(You can read the full research report on Walmart here >>>)
Shares of BHP Group have gained +67% over the past six months against the Zacks Mining - Miscellaneous industry’s rise of +18%. The Zacks analyst believes that its strong cash flow and focus on lowering debt will help it sail through these turbulent times. BHP Group is making operations more efficient on the back of smarter technology adoption across the entire value chain, which in turn will drive results.
BHP Group’s copper and iron ore production improved year over year in the nine-month period ended Mar 31, 2020, while petroleum, metallurgical coal, energy coal and nickel production declined. The company affirmed production and cost guidance for fiscal 2020 despite the pandemic.
The company will also benefit from the recent surge in iron and copper prices. The consensus estimate for earnings for the current fiscal year has thus undergone positive revisions lately. It has six major projects under development in petroleum, copper, iron ore and potash, which will drive growth in the long run.
(You can read the full research report on BHP here >>>)
IBM shares have lost -3.2% over the past three months against the S&P 500’s rise of +13.4%. This underperformance notwithstanding, the Zacks analyst believes that IBM is well placed in the hosted cloud, security and analytics domains.
Moreover, Red Hat acquisition has helped IBM to enhance containerized software capabilities and strengthen competitive position in the hybrid cloud market. Further, growing clout of Watson Health and growth in Payer, Provider, Imaging and Life Sciences verticals are noteworthy. Also, gains from z15 hold promise.
However, stiff competition in the cloud computing market remains a woe. Notably, adoption of cognitive applications and transaction processing platforms in March was affected by coronavirus outbreak, which is a major concern. For 2020, IBM has withdrawn guidance, citing uncertainty pertaining to coronavirus crisis. Also, a highly leveraged balance sheet, adds to the risks.
(You can read the full research report on IBM here >>>)
Other noteworthy reports we are featuring today include Costco Wholesale (COST), Citigroup (C) and Morgan Stanley (MS).
5 Stocks to Soar Past the Pandemic: In addition to the companies you learned about above, we invite you to learn about 5 cutting-edge stocks that could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of the decade.
See the 5 high-tech stocks now>>
Sheraz Mian
Director of Research
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Walmart's (WMT) Top Line Gains From Coronavirus-Led Demand
Liquidity, High Iron Prices to Aid BHP Group (BHP)
Robust Adoption of Cloud Solutions Aids IBM Amid High Debt
Featured Reports
Decent Comps to Fuel Costco's (COST) Sales, Cost a Concern
Per the Zacks analyst, Costco's growth strategies, decent comps run and strong membership trends are likely to fuel sales.
Focus on Core Operations Aid Citigroup (C), Legal Woes Linger
Per the Zacks analyst, Citigroup is working hard on restructuring activities to focus on core operations aiding top-line growth.
Buyouts, Loans Support Morgan Stanley (MS) Amid Lower Rates
Per the Zacks analyst, inorganic growth strategy, focus on less capital-market dependent businesses and decent loan demand will support Morgan Stanley.
Bayer (BAYRY) Boasts Strong Portfolio Amidst Competition
Per the Zacks analyst, Bayer's pharmaceutical products launched over the last few quarters should continue to drive top line at the company.
Southern Company (SO) Buoyed by Regulated Customer Growth
The Zacks analyst believes that increase in Southern Company's regulated business customer base will support its revenue growth.
Permian Focus Aids Occidental (OXY) Amid Rising Debt Level
Per the Zacks analyst Occidental's acquisition of Anadarko expanded its operation in resource rich Permian Basin, but its long term debt level is a concern amid choppy commodity prices and demand.
Strong PCR Product Sales Aid Bio-Rad (BIO) amid Pandemic Woes
The Zacks analyst is impressed with uptick in Bio-Rad's core PCR and Droplet Digital PCR product revenues resulting from robust COVID-19 testing demand.
New Upgrades
Papa John's (PZZA) Rides on Digital & Franchising Initiatives
Per the Zacks analyst, Papa John's benefits from product innovations, strategic partnerships, international expansion and franchising efforts.
Viper Energy (VNOM) Banks on Eagle Ford & Permian Acreages
The Zacks analyst believes that Viper Energy will generate strong and steady royalty income from mineral interests in the Eagle Ford & Permian acreages.
Sally Beauty (SBH) Gains From Online Sales Amid COVID-19
Per the Zacks analyst, Sally Beauty (SBH) is gaining from solid online sales amid COVID-19. Notably, management expects triple-digit e-commerce growth across all segments in fiscal third-quarter.
New Downgrades
Higher DTC Losses & Debt Hinders Disney's (DIS) Progress
Per the Zacks analyst, coronavirus-led uncertainty, higher operating losses in Direct-to-Consumer (DTC) business and a debt-ridden balance sheet are expected to impede Disney's growth.
CDW's Growth Prospects to be Hurt by Lower IT Spending
Per the Zacks Analyst, CDW's growth prospects might be hurt by soft IT spending as organizations are pushing back their investments in big and expensive tech products amid the coronavirus crisis.
Consumer Activity Disruptions Amid COVID-19 Ails Yelp (YELP)
Per the Zacks analyst, coronavirus-led restrictions on public life are hurting restaurants and retail, which pay Yelp to provide their information online. This, in turn, is affecting Yelp's top line.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Walmart Inc. (WMT): Free Stock Analysis Report
Morgan Stanley (MS): Free Stock Analysis Report
International Business Machines Corporation (IBM): Free Stock Analysis Report
Costco Wholesale Corporation (COST): Free Stock Analysis Report
Citigroup Inc. (C): Free Stock Analysis Report
BHP Group Limited (BHP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Sure Rubio is finally on board as Miami sinks into Biscayne Bay and the Atlantic.
Closed WMT again- 0 profit. No money for me in this market given my strategy and trading determinants.
I'll just maintain my core position in WMT at a 65.20 cost basis. Not to bother trading this.
Wow what a day. Out of PFE at 33.40 cost.
Added to IBM at 116
Reduced HT at an absolutely horrendous loss.
What I don't really get and maybe someone can explain to me-
NKLA hasn't manufactured one truck. Given its operating parameters its long haul capabilities are no where near Hyliion's.. or TSLA's.
https://www.ttnews.com/articles/hyliion-electrified-powertrain-steps-go-1000-miles-tank.
Tortoise SPAC (SHLL) and Hyliion are merging. Hyliion's technology is proven and working in a variety of long and short haul vehicles.
Workhorse (WKHS) https://workhorse.com/
Has a commercial van that's in production. https://workhorse.com/cseries.html
Contrasting again to NKLA;'s pipedream . What gives ?
https://nikolamotor.com/
Then there's SOLO, Electrameccanica Vehicles Corp with their silly non descript 3 wheel one person vehicle that no one would walk away from an accident, and some beautiful prototypes.
https://electrameccanica.com/eroadster/
https://electrameccanica.com/tofino/
Yet NKLA runs up and down faster than Disney's Rockin' Rollercoaster.
We're number 1 again ! USA USA ! Greatness is measured in numbers. Yes !
I don't really get your point SF.
Busy morning up near dawn.
Opened:
TWTR
SOLO
DOCU
Re opened WMT
Added to SHLL. WKHS
Avoided NKLA, though it's skyrocketing again.
Out of WMT on a stop loss at 124.50. 0 profit. I'll have my regrets about this stop soon enough. I'd rather not lose money than make money at this point. No red is my motto.
Eh, it's good Mangoes are virtually free for you and convenient for you and the critters. Personally I'm not a mango man, it upsets urinary equilibrium. Just sayin'. Probably too much information. Oh well.
Re-opened 1/2 position in SHLL at $25.95
Now there are so many services available. We did insta-cart- price gouging at Wegman's supermarket. TRGT had some nice items but not much, COST is really good. Even though insta-cart delivers when you couple your prescriptions with other items COST waives the $35 delivery charge there's still an insta-cart mark up. Misfits Market is good also, providing fresh veggies. We went to a local butcher and filled the freezer in March and are still going through those meats. My GF is a prodigious chef and uses a huge variety of food items. Also Boxed is a great supplier to the home. They are really great. Affiliated with Aldi and Lidl. We've used them consistently and they're really great. Really really great.
Now I just want to kill myself about NEE sold too soon after watching it go down over $10 a share and all of a sudden hits where my original sell target would have been activated around $253. Damn !
Have buy in for $246 on NEE, maybe lower... It'll hit as their earnings come out.
Zacks.com featured highlights include: Teekay Tankers, Tesla, NextEra Energy, Nice and West Pharmaceutical Services
9:07 am ET July 6, 2020 (Zacks) Print
For Immediate Release
Chicago, IL – July 6, 2020 – Stocks in this week’s article are Teekay Tankers TNK, Tesla Inc. TSLA, NextEra Energy NEE, Nice Ltd NICE and West Pharmaceutical Services WST.
5 Low-Leverage Stocks to Buy Amid Coronavirus-Led Debacle
Leverage, otherwise termed as debt financing, is the use of exogenous funds by corporations to run their operations smoothly and expand the same. Although there is an option for equity financing, historically, debt financing has been preferred over equity because of its easy and cheap availability.
However, one should keep in mind that debt financing remains a feasible option as long as the companies succeed in generating a higher rate of return compared to the interest rate. Exorbitant debt financing might even lead to a corporation’s bankruptcy in the worst-case scenario.
Given the ongoing economic turmoil prevalent across the globe, courtesy of the coronavirus pandemic, investors should know that uncertainty can hit the global equity market anytime and therefore it is better to take measures beforehand than repent later.
Particularly, they should be aware of leverage, or in other words, how much debt a company owns.
This is because the higher the degree of financial leverage, higher is the interest payment for the capital borrowed.
And here comes the importance of leverage ratios, which have been constructed to safeguard investors from becoming victims of debt trap. Debt-to-equity ratio is one such measure, perhaps the most popular one, to evaluate a company’s creditworthiness for potential equity investments.
Analyzing Debt/Equity
Debt-to-Equity Ratio = Total Liabilities/Shareholders’ Equity
This metric is a liquidity ratio that indicates the amount of financial risk a company bears. A company with a lower debt-to-equity ratio shows improved solvency for a company.
With Q2 earnings in front of us, investors may intend to choose companies that have exhibited solid earnings growth. However, blindly pursuing high earnings yielding stocks, which have a high debt-to-equity ratio, might drain all your money before you know.
For the rest of this Screen of the Week article please visit Zacks.com at:https://www.zacks.com/stock/news/996967/5-low-leverage-stocks-to-buy-amid-coronavirusled-debacle
Good point, if I put an item in my cart on AZMN and go back to it later many times I find that its gone up in price. So I either remove it or put it aside and eventually it'll come down. Most times the best price I find on ANZN is the best price on AMZN. If I don't buy then I may pay more. But AMZN is funny. If I look around sometimes I find a comparable item for less that wasn't there before. Crazy.
Incidentally- Fla. just printed that it has 10,000 new covid infections today and the US has 3 mill cases. Number one baby. Great again!
Oh, co- incidentally added to EPD at 17.60.
One might have thought that T going ex div would have run up a bit more. Nope.
There are many places that have lower prices on many items Walmart sells. But there is an advantage at times to shop there. Either online or at the store.
Case in point- many folks shop at WMT thinking they're getting best price because Walmart says its prices are lowest. Not true and the same can be said of AMZN EBAY COST BJ BBY BBBY WMT Sam's club etc etc etc.
I look all around find the best price bottom line and go for it.
Just a couple of points-
AMZN may have a deep library of films, but many of them are for added pay. If you wanted to see a full 10 episode series on AMZN at 3.99 per episode it'd cost you 39.99 which is ridiculous.
When looking to stay at home recently when all this came about, all food services were booked or didn't have product. Walmart not only had product but was able to deliver. So there's that. And I don't even have their annual pay service.
Out of NEE, I don't have the patience for laggards and closed at 249.50 from an open of 248.40.
Also out of SHLL at 26.55. 0 profit. Bad price action. will reopen lower.
Nothing compared to what you managed with NVAX and PM today Nick. Looks to me like you ate someone else's lunch with NVAX today.
Added to WMT at 124.50, last trimmed at 132. We'll see if I can get 132 again.
I'm on a few Redskins store sights now. I'll buy a few now defunct Redskins items, hats, jerseys. Not for sale on Ebay. I'm in no way ideologically fixated on this, just a collector. Also ordered a Mississippi flag on Amazon. Historic relics from a soon to be past.
Well Nick even Warren Buffet doesn't Expect the Spanish Inquisition all of the time...
Closed HST at $11.40.
Closed COST from $299 to $309. Okay. I could have been watching and gotten more...Oh well.
Nice work Court. Looking good. Bet you can't wait to take her out for a spin.
Thanks SF,
Good take on reality and funny too.
Hope all had a good time this past weekend, and didn't blow your noses off.
I took the 3 day and had a great time.
Last Thursday opened these 3:
07/01/2020 11:54:14 Bought DNB @ 25.37
07/02/2020 13:11:11 Bought WKHS @ 20.75
07/02/2020 15:49:51 Bought PDCO @ 22
Filled ( Partial ) Sell HST Limit
$11.40 19:58:32 07/02/20.
This last one is throwing in the towel. Part of my income portfolio that isn't generating as much income these days. HST being one of those so- BYE !
opened WKHS at $20.75
Had my sell order in since shortly ago. That's a determination that I had made based on technicals viewing the market movements and charting. I think it was a good trade.
But yes If I was awake this morning I might have been monitoring this and gotten another $1.oo per share out of it, but I'll take what I got.... and I'll buy it back when the time is right. Or not. It's a good company, but I'm not concerned about investing in good companies, I'm interested in trading good companies.
So maybe next time I'll be awake and have my Wheaties earlier in the day. Too much online streaming at keeping me up at night. Other than a look or two on snooze in the morning at 6am, 7am 8am and 9,at the markets and at buy/sell orders, I sleep. My bad. Doesn't make for a great stock trader I know.
Now that's a wake up call. I know you're just kidding, but it's true, had I been up this morning I would have been watching this sale and MAYBE gotten a bit more. MAYBE.
There is no doubt that inflation is on its way. Higher and restrictive interest rates too. The question is when and whether it'll be within our lifetimes. Global economies are in such bad shape that the immediacy of interest rate increases a not a concern.
On 6 /25/20 opened SAH at $29.70, closed this morning at $33.20 before I had my Wheaties.
I'm reluctant to sell to close anything more until there's a pronounced move. May trim a bit though.
Nee is up over $6 today, but no word or news as to why. Calendar is empty, no dividend or earnings coming up soon. Only thing is that utilities in general have been battered recently because of added CV cases in US. But now all of a sudden everything is peachy keen because PFE and BNTX might have a vaccine in their dreams.
So what do you make of this + $6 phenomena ?
I also mentioned cyber security companies as well. When blinded by a major catastrophic event like CV19 it's easy to lose track of the folks prying in to your security mechanisms. Hence it's easy to forget about cyber security firms. So I mention this again, because I believe that cyber security will continue to be a major issue going forward and is still a good long term investment.
Nick,
What do you think about the possibility that BP may have to reduce their dividend considering that they borrowed to pay it and their EPS is negative?
This is an ongoing concern and since becoming aware of this I've decided to cancel adding to BP at 22.60. From an article read this morning it appears that BP is basing their dividend payments on the assumption that oil will rebound to $60 a barrel.
On the other hand opened DNB at $25.37 on another one of those beautiful IPOs.
Morokoy,
Out of LCA on a stop loss at 15. 0 profit.
Oh well.
Closed TQQQ ast 99.50 from 6/25/20 purchase @94 in IRA portfolio.
Thanks Nick, That's one way to do it.
Stopped partly out at 25.70 from a 24 cost- for 1/3 SHLL.
Nick-
So where do I sell this now from a recent buy at $33.40 ...
9:02 am ET
*Pfizer and BioNTech shares are trading higher after the companies announced data from their BNT162 mRNA-based coronavirus vaccine program.(Benzinga)
Pfizer, BioNTech Press Release Confirms Early Positive Data From Ongoing Phase 1/2 Study Of Coronavirus Vaccine Candidate
9:00 am ET July 1, 2020 (Benzinga) Hot Stories Print
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) today announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic. The BNT162 program is evaluating at least four experimental vaccines, each of which represents a unique combination of mRNA format and target antigen. The manuscript describing the preliminary clinical data for the nucleoside-modified messenger RNA (modRNA) candidate, BNT162b1, which encodes an optimized SARS-CoV-2 receptor binding domain (RBD) antigen, is available on an online preprint server at https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1 and is concurrently undergoing scientific peer-review for potential publication. Overall, the preliminary data demonstrated that BNT162b1 could be administered in a dose that was well tolerated and generated dose dependent immunogenicity, as measured by RBD-binding IgG concentrations and SARS-CoV-2 neutralizing antibody titers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200701005576/en/
“We are encouraged by the clinical data of BNT162b1, one of four mRNA constructs we are evaluating clinically, and for which we have positive, preliminary, topline findings,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We are dedicated to develop potentially groundbreaking vaccines and medicines, and in the face of this global health crisis, we approach this goal with the utmost urgency. We look forward to publishing our clinical data in a peer-reviewed journal as quickly as possible.”
“These preliminary data are encouraging in that they provide an initial signal that BNT162b1 targeting the RBD SARS-CoV-2 is able to produce neutralizing antibody responses in humans at or above the levels observed in convalescent sera – and that it does so at relatively low dose levels. We look forward to providing further data updates on BNT162b1,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech.
The ongoing U.S. Phase 1/2 randomized, placebo-controlled, observer-blinded study is evaluating the safety, tolerability, and immunogenicity of escalating dose levels of BNT162b1. The initial part of the study included 45 healthy adults 18 to 55 years of age. Preliminary data for BNT162b1 was evaluated for 24 subjects who received two injections of 10 µg and 30 µg, 12 subjects who received a single injection of 100 µg, and 9 subjects who received 2 doses of placebo control.
The participants received two doses, 21 days apart, of placebo, 10 µg or 30 µg of BNT162b1, or received a single dose of 100 µg of the vaccine candidate. Because of a strong vaccine booster effect, the highest neutralizing titers were observed seven days after the second dose of 10 µg or 30 µg on day 28 after vaccination. The neutralizing GMTs were 168 and 267 for the 10 µg and 30 µg dose levels, respectively, corresponding to 1.8- and 2.8-times the neutralizing GMT of 94 observed in a panel of 38 sera from subjects who had contracted SARS-CoV-2.
In all 24 subjects who received 2 vaccinations at 10 µg and 30 µg dose levels of BNT162b1, elevation of RBD-binding IgG concentrations was observed after the second injection with respective GMCs of 4,813 and 27,872 units/ml at day 28, seven days after immunization. These concentrations are 8- and 46.3-times the GMC of 602 units/ml in a panel of 38 sera from subjects who had contracted SARS-CoV-2.
At day 21 after a single injection, the 12 subjects who received 100 µg of BNT162b1 had an RBD-binding IgG GMC of 1,778 units/ml and a SARS-CoV neutralizing GMT of 33, which are 3-times and 0.35-times, respectively, the GMC and GMT of the convalescent serum panel.
At the 10 µg or 30 µg dose levels, adverse reactions, including low grade fever, were more common after the second dose than the first dose. Following dose 2, 8.3% of participants who received 10 µg and 75.0% of participants who received 30 µg BNT162b1 reported fever ≥ 38.0 °C. Local reactions and systemic events after injection with 10 µg and 30 µg of BNT162b1 were dose-dependent, generally mild to moderate, and transient. The most commonly reported local reaction was injection site pain, which was mild to moderate, except in one of 12 subjects who received a 100 µg dose, which was severe. No serious adverse events were reported. Given higher numbers of subjects experiencing local reactions and systemic events after a single 100 µg dose with no significant increases in immunogenicity compared to the 30 µg dose level, the 12 participants in the 100 µg group were not administered a second dose.
These preliminary data, together with additional preclinical and clinical data being generated, will be used by the two companies to determine a dose level and select among multiple vaccine candidates to seek to progress to a large, global Phase 2b/3 safety and efficacy trial. That trial may involve up to 30,000 healthy participants and is anticipated to begin in late July 2020, if regulatory approval to proceed is received. The preliminary clinical data from this ongoing study have been submitted for potential publication in a peer-reviewed journal and is available on an online preprint manuscript server.
The BNT162b1 candidate remains under clinical study and is not currently approved for distribution anywhere in the world. If the ongoing studies are successful and the vaccine candidate receives regulatory approval, the companies expect to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021. In that event, BioNTech and Pfizer would work jointly to distribute the potential COVID-19 vaccine worldwide (excluding China, where BioNTech has a collaboration with Fosun Pharma for BNT162 for both clinical development and commercialization). The development of the vaccine is also supported by partners like Acuitas Therapeutics. The Canadian company provides lipid nanoparticles (LNP) for the formulation of various mRNA vaccines.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.